STK11 - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	CCNE1	cyclin E1	G0 and Early G1 SCF(Skp2)-mediated degradation of p27/p21 DNA Damage/Telomere Stress Induced Senescence Association of TriC/CCT with target proteins during biosynthesis TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest CDK-mediated phosphorylation and removal of Cdc6 Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes Cyclin E associated events during G1/S transition G1/S-Specific Transcription Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response PTK6 Regulates Cell Cycle Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) RHOBTB3 ATPase cycle		Laryngeal cancer Gastric cancer
Novel	CD44	CD44 molecule (IN blood group)	Degradation of the extracellular matrix Cell surface interactions at the vascular wall Hyaluronan metabolism Integrin cell surface interactions Hyaluronan degradation Neutrophil degranulation Interferon gamma signaling Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Bivatuzumab Hyaluronic acid	Gastric cancer
Novel	CDC14B	cell division cycle 14B	MAPK6/MAPK4 signaling
Novel	CDC37	cell division cycle 37, HSP90 cochaperone	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Constitutive Signaling by EGFRvIII Regulation of necroptotic cell death Downregulation of ERBB2 signaling RHOBTB2 GTPase cycle Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants
Novel	CDK4	cyclin dependent kinase 4	SCF(Skp2)-mediated degradation of p27/p21 Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence RMTs methylate histone arginines Transcriptional regulation of white adipocyte differentiation Cyclin D associated events in G1 Ubiquitin-dependent degradation of Cyclin D Ubiquitin-dependent degradation of Cyclin D PTK6 Regulates Cell Cycle Transcriptional regulation by RUNX2 Meiotic recombination Transcriptional regulation of granulopoiesis Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity SPOP-mediated proteasomal degradation of PD-L1(CD274)	Purvalanol Alvocidib Palbociclib Ribociclib Abemaciclib Fostamatinib Trilaciclib	Malignant melanoma Glioma Cervical cancer
Novel	CDK6	cyclin dependent kinase 6	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 Regulation of RUNX1 Expression and Activity Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity	Alvocidib (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol Fisetin Palbociclib Ribociclib Abemaciclib Trilaciclib
Novel	CDKN2A	cyclin dependent kinase inhibitor 2A	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 Transcriptional Regulation by VENTX Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Apoptotic factor-mediated response Oxidative Stress Induced Senescence Oncogene Induced Senescence SUMOylation of DNA damage response and repair proteins SUMOylation of transcription factors Regulation of TP53 Degradation Stabilization of p53 Regulation of RUNX3 expression and activity Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function Evasion of Oncogene Induced Senescence Due to p14ARF Defects Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects Nuclear events mediated by NFE2L2		Chronic myeloid leukemia (CML) Non-small cell lung cancer Malignant islet cell carcinoma Adult T-cell leukemia Esophageal cancer Glioma Pancreatic cancer Nasopharyngeal cancer Hepatocellular carcinoma Squamous cell carcinoma Penile cancer Oral cancer Malignant melanoma Burkitt lymphoma Gallbladder cancer Bladder cancer Laryngeal cancer Cholangiocarcinoma Malignant pleural mesothelioma Osteosarcoma Type II diabetes mellitus
Novel	CDKN2B	cyclin dependent kinase inhibitor 2B	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1		Type II diabetes mellitus Osteosarcoma Malignant pleural mesothelioma
Novel	CDKN2C	cyclin dependent kinase inhibitor 2C	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1
Novel	CFL2	cofilin 2			Nemaline myopathy
Novel	CRY2	cryptochrome circadian regulator 2	Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex Phosphorylation and nuclear translocation of the CRY:PER:kinase complex Degradation of CRY and PER proteins
Novel	CTSB	cathepsin B	Collagen degradation Trafficking and processing of endosomal TLR Assembly of collagen fibrils and other multimeric structures MHC class II antigen presentation Neutrophil degranulation Degradation of CDH1	2-Aminoethanimidic Acid 3-Amino-4-Oxybenzyl-2-Butanone 3-Methylphenylalanine N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline 2-Pyridinethiol Diphenylacetic acid N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane N-{[(2S,3S)-3-(Ethoxycarbonyl)-2-oxiranyl]carbonyl}-L-threonyl-L-isoleucine N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE	Tropical calcific pancreatitis
Novel	CYLC2	cylicin 2
Novel	CYP17A1	cytochrome P450 family 17 subfamily A member 1	Androgen biosynthesis Glucocorticoid biosynthesis Defective CYP17A1 causes AH5	NADH Progesterone Spironolactone Ketoconazole Levoketoconazole Abiraterone Cannabidiol Medical Cannabis Nabiximols	Congenital adrenal hyperplasia (CAH) 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
Novel	D2HGDH	D-2-hydroxyglutarate dehydrogenase	Interconversion of 2-oxoglutarate and 2-hydroxyglutarate
Novel	DACH1	dachshund family transcription factor 1
Novel	EEF1A2	eukaryotic translation elongation factor 1 alpha 2	Eukaryotic Translation Elongation	Plitidepsin
Novel	EPHA2	EPH receptor A2	EPH-Ephrin signaling EPH-Ephrin signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse EPH-ephrin mediated repulsion of cells EPH-ephrin mediated repulsion of cells RAC1 GTPase cycle RAC2 GTPase cycle RHOG GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle	Dasatinib Phosphoaminophosphonic Acid-Adenylate Ester Regorafenib Fostamatinib
Novel	ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Breast cancer Cervical cancer Cholangiocarcinoma Pancreatic cancer Gastric cancer Ovarian cancer Choriocarcinoma Endometrial Cancer Bladder cancer
Novel	ERLEC1	endoplasmic reticulum lectin 1	ABC-family proteins mediated transport Hedgehog ligand biogenesis Hh mutants are degraded by ERAD Defective CFTR causes cystic fibrosis AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)

Search Results for: STK11